← brief for 2026-10-07 · People & money

Cost-effectiveness of dapagliflozin for the treatment of chronic kidney disease: a systematic review

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This review analyzed 14 studies on the cost and benefit of a drug called dapagliflozin. It is used to treat both diabetes and kidney disease. The review found that the drug is a good value for treating kidney disease. This helps doctors and health systems decide if the drug is worth the cost.

Who did this work

Zehui Jiang (Jiangxi University of Traditional Chinese Medicine) · Nannan Yan (Jiangxi University of Traditional Chinese Medicine) · Dongxiao Chen (Jiangxi University of Traditional Chinese Medicine) · Cai Xiao (Jiangxi University of Traditional Chinese Medicine) · Fei Le (Jiangxi University of Traditional Chinese Medicine) · Jun Zhang (People's Liberation Army 401 Hospital)

Source

Article · OpenAlex, CKD works · 2026-10-06
https://doi.org/10.1186/s12962-026-00817-x